Literature DB >> 29138914

Impact of "Tailored" Parathyroidectomy for Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1.

Kiyomi Horiuchi1, Momoko Sakurai2, Kento Haniu2, Erin Nagai2, Hiroki Tokumitsu2, Yusaku Yoshida2, Yoko Omi2, Akiko Sakamoto2, Takahiro Okamoto2.   

Abstract

BACKGROUND: Whether total parathyroidectomy (TPTX) or subtotal parathyroidectomy (SPTX) should be performed for primary hyperparathyroidism (PHPT) in patients with multiple endocrine neoplasia type 1 (MEN1) is controversial. At our institution, the parathyroidectomy strategy is based on the number of enlarged intraoperative parathyroid glands. We retrospectively analyzed our parathyroidectomy procedures.
METHODS: Data of PHPT treatment in patients with MEN1 who underwent parathyroidectomy from 1982 to 2012 at our department were retrospectively collected. The data were grouped according to the surgical procedure: TPTX, SPTX, and less than SPTX (LPTX). TPTX or SPTX was selected based on the preoperative examination findings and number of enlarged intraoperative parathyroid glands. The outcomes were the disease-free survival (DFS) rate and postoperative calcium replacement rate based on Kaplan-Meier analysis for each type of surgical procedure.
RESULTS: Forty-five patients were analyzed. The overall 5- and 10-year DFS was 91.7 and 55.8%, respectively. The 5- and 10-year DFS in each subgroup was 100.0 and 85.7% in the TPTX group, 89.4 and 57.3% in the SPTX group, and 91.6 and 57.3% in the LPTX group, respectively. The postoperative calcium replacement rate at 1 and 12 months was 91.7 and 58.3% in the TPTX group, 21.1 and 7.0% in the SPTX group, and 30.0 and 0.0% in the LPTX group, respectively.
CONCLUSIONS: Although LPTX was not satisfactory as a standard procedure, both SPTX and TPTX are effective treatment methods for PHPT in patients with MEN1. The parathyroidectomy strategy should be based on intraoperative evaluation of the parathyroid glands.

Entities:  

Mesh:

Year:  2018        PMID: 29138914     DOI: 10.1007/s00268-017-4366-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved.

Authors:  L O UNDERDAHL; L B WOOLNER; B M BLACK
Journal:  J Clin Endocrinol Metab       Date:  1953-01       Impact factor: 5.958

2.  Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism.

Authors:  Mark Versnick; Aleksandra Popadich; Stan Sidhu; Mark Sywak; Bruce Robinson; Leigh Delbridge
Journal:  Surgery       Date:  2013-07       Impact factor: 3.982

3.  Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.

Authors:  Maria D Balsalobre Salmeron; Jose Manuel Rodriguez Gonzalez; Joan Sancho Insenser; Joan Sancho Fornos; Albert Goday; Nuria Maria Torregrosa Perez; Antonio Rios Zambudio; Pascual Parrilla Paricio; Antonio Sitges Serra
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

4.  Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential?

Authors:  C Dotzenrath; K Cupisti; P E Goretzki; Q Yang; D Simon; C Ohmann; H D Röher
Journal:  Eur J Surg       Date:  2001-03

Review 5.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

6.  Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Laura A Lambert; Suzanne E Shapiro; Jeffrey E Lee; Nancy D Perrier; Mylene Truong; Michael J Wallace; Ana O Hoff; Robert F Gagel; Douglas B Evans
Journal:  Arch Surg       Date:  2005-04

7.  Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Dina M Elaraj; Monica C Skarulis; Steven K Libutti; Jeffrey A Norton; David L Bartlett; James F Pingpank; Fathia Gibril; Lee S Weinstein; Robert T Jensen; Stephen J Marx; H Richard Alexander
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

8.  The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.

Authors:  Anathea C Powell; H Richard Alexander; James F Pingpank; Seth M Steinberg; Monica Skarulis; David L Bartlett; Sunita Agarwal; Craig Cochran; Geoffrey Seidel; Douglas Fraker; Marybeth S Hughes; Robert T Jensen; Stephen J Marx; Steven K Libutti
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

9.  Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?

Authors:  Francesco Tonelli; Tommaso Marcucci; Geri Fratini; Maria Silvia Tommasi; Alberto Falchetti; Maria Luisa Brandi
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

10.  Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure.

Authors:  Naris Nilubol; Lee S Weinstein; William F Simonds; Robert T Jensen; Stephen J Marx; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2015-11-05       Impact factor: 5.344

View more
  8 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

Review 2.  Less Than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.

Authors:  Damien Bouriez; Caroline Gronnier; Magalie Haissaguerre; Antoine Tabarin; Haythem Najah
Journal:  World J Surg       Date:  2022-06-29       Impact factor: 3.282

3.  Multiple endocrine neoplasia type 1 involving both the liver and lung: a case report.

Authors:  Jianlin Lai; Yangyang Huang; Junyi Wu; Hui Cheng; Funan Qiu
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

4.  Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism.

Authors:  Hye Ryeon Choi; Sun Hyung Choi; Soon Min Choi; Jin Kyong Kim; Cho Rok Lee; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Seunghyun Lee; Namki Hong; Yumie Rhee
Journal:  Sci Rep       Date:  2020-06-30       Impact factor: 4.379

5.  Total and Subtotal Parathyroidectomy in Young Patients With Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism: Potential Post-surgical Benefits and Complications.

Authors:  Francesco Tonelli; Francesca Marini; Francesca Giusti; Maria Luisa Brandi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-24       Impact factor: 5.555

6.  Editorial: Early Genetic and Clinical Diagnosis in MEN1.

Authors:  Delmar M Lourenço; Wouter W de Herder
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-15       Impact factor: 5.555

Review 7.  Recent advances in the understanding and management of primary hyperparathyroidism.

Authors:  Melanie Goldfarb; Frederick R Singer
Journal:  F1000Res       Date:  2020-02-25

8.  Parathyroid venous sampling for the preoperative localisation of parathyroid adenoma in patients with primary hyperparathyroidism.

Authors:  Joon Ho; Donggyu Kim; Ji-Eun Lee; Namki Hong; Byung Moon Kim; Dong Joon Kim; Jinkyong Kim; Cho Rok Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Yumie Rhee
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.